468 related articles for article (PubMed ID: 23580575)
21. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
Song L; Morris M; Bagui T; Lee FY; Jove R; Haura EB
Cancer Res; 2006 Jun; 66(11):5542-8. PubMed ID: 16740687
[TBL] [Abstract][Full Text] [Related]
22. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.
Azijli K; Yuvaraj S; Peppelenbosch MP; Würdinger T; Dekker H; Joore J; van Dijk E; Quax WJ; Peters GJ; de Jong S; Kruyt FA
J Cell Sci; 2012 Oct; 125(Pt 19):4651-61. PubMed ID: 22797920
[TBL] [Abstract][Full Text] [Related]
23. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA
Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114
[TBL] [Abstract][Full Text] [Related]
24. Molecular detection of SS18-SSX fusion gene transcripts by cRNA in situ hybridization in synovial sarcoma using formalin-fixed, paraffin-embedded tumor tissue specimens.
Kanemitsu S; Hisaoka M; Shimajiri S; Matsuyama A; Hashimoto H
Diagn Mol Pathol; 2007 Mar; 16(1):9-17. PubMed ID: 17471153
[TBL] [Abstract][Full Text] [Related]
25. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.
Watanabe T; Tsuda M; Makino Y; Ichihara S; Sawa H; Minami A; Mochizuki N; Nagashima K; Tanaka S
Mol Cancer Res; 2006 Jul; 4(7):499-510. PubMed ID: 16849525
[TBL] [Abstract][Full Text] [Related]
26. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.
Mpakou VE; Kontsioti F; Papageorgiou S; Spathis A; Kottaridi C; Girkas K; Karakitsos P; Dimitriadis G; Dervenoulas I; Pappa V
Leuk Res; 2013 Feb; 37(2):175-82. PubMed ID: 23149070
[TBL] [Abstract][Full Text] [Related]
28. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
29. SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation.
Xie Y; Skytting B; Nilsson G; Gasbarri A; Haslam K; Bartolazzi A; Brodin B; Mandahl N; Larsson O
Cancer Res; 2002 Jul; 62(13):3861-7. PubMed ID: 12097301
[TBL] [Abstract][Full Text] [Related]
30. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
31. The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.
de Bruijn DR; Allander SV; van Dijk AH; Willemse MP; Thijssen J; van Groningen JJ; Meltzer PS; van Kessel AG
Cancer Res; 2006 Oct; 66(19):9474-82. PubMed ID: 17018603
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
33. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
[TBL] [Abstract][Full Text] [Related]
34. A novel fusion gene, SS18L1/SSX1, in synovial sarcoma.
Storlazzi CT; Mertens F; Mandahl N; Gisselsson D; Isaksson M; Gustafson P; Domanski HA; Panagopoulos I
Genes Chromosomes Cancer; 2003 Jun; 37(2):195-200. PubMed ID: 12696068
[TBL] [Abstract][Full Text] [Related]
35. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
36. Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma.
Friedrichs N; Trautmann M; Endl E; Sievers E; Kindler D; Wurst P; Czerwitzki J; Steiner S; Renner M; Penzel R; Koch A; Larsson O; Tanaka S; Kawai A; Schirmacher P; Mechtersheimer G; Wardelmann E; Buettner R; Hartmann W
Int J Cancer; 2011 Oct; 129(7):1564-75. PubMed ID: 21128248
[TBL] [Abstract][Full Text] [Related]
37. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
38. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.
Kawai A; Woodruff J; Healey JH; Brennan MF; Antonescu CR; Ladanyi M
N Engl J Med; 1998 Jan; 338(3):153-60. PubMed ID: 9428816
[TBL] [Abstract][Full Text] [Related]
39. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
